Experimental study to develop Src-targeted molecular therapy in small cell lung cancer
Experimental study to develop Src-targeted molecular therapy in small cell lung cancer
小细胞肺癌Src靶向分子治疗的实验研究
批准号：
22501044
负责人：
IGISHI Tadashi
金额：
$2.25万
依托单位：
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2010
资助国家：
日本
项目状态：
已结题
起止时间：
2010 至 2012
中文摘要
翻译
在小细胞肺癌标本中检测干细胞因子/c-kit和胰岛素样生长因子- i (IGF-I)/IGF-I受体。在小细胞肺癌细胞系H209细胞中，干细胞因子和igf - 1均可诱导氨柔比星耐药。Src抑制剂达沙替尼恢复了对amrubicinin干细胞因子处理的H209细胞的敏感性。然而，达沙替尼不影响igf -i诱导的氨柔比星耐药。
英文摘要
Stem cell factor/c-kit and insulin-like growth factor-I(IGF-I)/IGF-I receptor were detected in small cell lung cancer specimens. In small cell lung cancer cell line, H209 cells, both stem cell factor and IGF-I induced amrubicin resistance. A Src inhibitor, dasatinib, restored the sensitivity to amrubicinin stem cell factor-treated H209 cells. However, dasatinib did not affected IGF-I-induced amrubicinresistance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
